Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

Presentation Operator Good morning, and welcome to Johnson Johnson's First Quarter 2025 Earnings Conference Call. [Operator ...

Chart of trends ... specific research of lung cancer. There is a significant overlap between #Cluster1 and #Cluster2, which is highly relevant to the research theme of this article. Many of the ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Treatment resistance ... to support the progression of lung adenocarcinoma, the most common type of non-small cell lung cancer. This work identifies a new mechanism by which agrin can support ...

is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung cancer treatment. Immune checkpoint inhibitors, a class of immunotherapies that help immune ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

You may have had chest radiation therapy in the past as a treatment for breast cancer or Hodgkin’s lymphoma. According to the American Cancer Society, around 1% to 2% of all lung cancer deaths ...

Efti's unique MHC Class 2 agonist mechanism shows strong efficacy and safety across PD-L1 levels in lung cancer trials. The trial will enroll 756 patients globally, with randomization to treatment or ...